Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
06 9월 2023 - 5:30AM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
today announced that the Company will participate in two upcoming
healthcare conferences.
- Thursday, September 7th, the Company will host investor
meetings at Citi’s 18th Annual BioPharma Conference in Boston,
MA.
- Wednesday, September 13th at 10:50am ET/7:50am PT, the Company
will participate in a fireside chat and also host investor meetings
at the 21st Annual Morgan Stanley Global Healthcare Conference in
New York, NY.
A live webcast of the Morgan Stanley fireside chat will be
available in the investor relations section of the Company’s
website at https://ir.alpineimmunesciences.com/events and a replay
will be available on the Company's website for 90 days following
the event.
About Alpine Immune
Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905389290/en/
Media and Investor Relations
Contact: Temre Johnson Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunesciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alpine Immune Sciences (NASDAQ:ALPN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024